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1. List of Abbreviations 
 
ALP Alkaline Phosphatase 
ATMP Advanced Therapy Medicinal Product 
BM Bone Marrow 
CD Cluster of Differentiation 
CM Conventional Method 
CFU Colony Forming Unit 
CPA Cryoprotectant Agent 
cAMP Cyclic Adenosine Monophosphate 
ddH2O Deionzed Water 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethyl Sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
FBS Fetal Bovine Serum 
FCS Fetal Calf Serum 
FSP Fibroblast Specific Protein 
GLP Good Laboratory Practice 
GM-CSF Granulocyte Macrophage Colony Stimulating Factor 
GMP Good Manufacturing Practice 
H2O2 Hydrogen Peroxide 
hES Human Embryonic Stem 
HES Hydroxyethyl Starch 
ICE Intracellular Ice  
kDa Kilodaltons 
MHC-II Major Histocompatibility Complex II 
MS Molar Substitution 
MSC Mesenchymal Stem Cells 
MTT 3-[4, 5-dimethyltiazol-2-yl]-2, 5-diphenyltetrazolium bromide 
MW Molecular Weight 
PBS Phosphate Buffered Saline 
PEG Polyethylene glycol 
PFA Paraformaldehyde 
PVP Polyvinylpyrrolidone 
QRM Quality Risk Management 
RBC Red Blood Cells 
ROS Reactive Oxygen Species 
SEM Standard Error of the Mean 
SMA-α Alpha-Smooth Muscle Actin 
Tg Glass-Transition Temperature 
TGF-β Tumor Growth Factor beta 








2 Introduction:  
In the field of regenerative medicine constant optimization of cryopreservation protocols for 
cells are on demand to enhance cell viability and to maintain cellular activities. In order to 
cryopreserve cells, freezing protocols and cryoprotectant agents have been developed but 
with varying degrees of success. The two main problems encountered by cryopreservation 
are: cryo-injury and cryoprotectant agent toxicity. Both affect cell recovery as well as cell 
functionality. Therefore, the studies presented in this thesis focus in the improvement and 
comparison of different freezing protocols and cryoprotectant agents for the cryopreservation 
of mesenchymal stem cells, fibroblasts and keratinocytes. In addition, toxicity of the 
cryoprotectant agent was analyzed and replacement with non-toxic solutions was performed.   
 
2.1 Cryopreservation overview 
2.1.1 Cryopreservation 
Cryopreservation is the process wherein biomaterials such as cells, tissues and organ, 
among others can be stored at subzero temperatures without affecting the molecular and 
biophysical structures. The idea of cryopreservation was reported in 1776 by Spallanzani 
who exposed human sperm to low temperature and observed that its motility was 
maintained. It was followed by Mantagazza in 1886 who suggested the idea of creating a 
human frozen sperm bank. The concept of cryopreservation was first established in 1948 by 
Polga et al when a glycerol-based solution was accidentally used instead of levulose for the 
preservation of bull spermatozoa [1]. From that moment on an increased interest in the study 
of cryopreservation processes and methods emerged.  
During the cryopreservation process water and aqueous solutions freeze below their melting 
point before nucleation of ice takes place, also known as supercooling. At this point, 
“seeding” can occur if the water or aqueous solution is touched with a metal object or crystal 
allowing for crystallization to occur after which the solution will return to its freezing point.  
The melting point is when the water or substance changes from their liquid state to a solid 
state, and the initial formation of ice is called nucleation. Formation of ice during the 
preservation process results in release of heat from the solution followed by nucleation (Fig 
1). The main challenge that cryopreservation faces is not the prolonged storage of cells at 
low temperatures but rather the lethality that the cells have to endure by passing twice the 
intermediate zone of temperature (~-15°C to -60°C), once during cooling and once during 
warming through. Fowler and Toner described that reaching -138°C without ice formation is 
possible if freezing occurs very fast or ice crystal formation is inhibited by the addition of 


























Representation of heat release during the cooling process utilizing different cryoprotectant agents. Heat release of 
the samples occurred between -2°C to -15°C for a slow cooling rate.   
 
2.1.2 Cryo-induced damaged 
During cryopreservation procedures injuries to the cells, tissues and organs are incurred 
which are lethal resulting in apoptosis or necrosis in most instances, and which are possibly 
due to osmotic imbalances, cryoprotectant toxicity, cooling and warming rates, among other 
things.  
In 1972 Mazur reported the “two-factor hypothesis” which stated that the correlation between 
cooling rates and survival is due to toxic effects of the cryosolution at low freezing rate or by 
















Figure 2.  Inversed U-shaped curve for the correlation between cell survival and cooling rate curve correlation in 
injury mechanism (Representative figure from Mazur [4]). 
 
The main hypothesis behind this is that avoidance of these 2 factors would lead to an optimal 
cryopreservation. But for an optimal cooling rate to be achieved, cellular survival is 
dependent on a freezing rate in which water can be retained inside the cell in order to 
prevent slow-freezing damage but which is slow enough that dehydration can occur without 
the formation of intracellular ice [2]. A correlation between cooling rate, ICE formation and 
cell survival can been seen in Figure 3. At higher freezing rates ICE formation increases 




















Comparison of the effect of cooling rates and its correlation with cell survival and intracellular ice formation for 
different mammalian cell types. Each color represents one cell type (Representative diagram from P. Mazur  [3] 
[5]). 
 
Mazur described that around -5°C the cell and its surroundings stay at an unfrozen state, and 
that between -5°C and -15°C ice is formed in the surrounding area either spontaneously or 
due to seeding but that the cell contents remain unfrozen and supercooled, as seen in Fig 4 
[5].  
 
Figure 4. Representation of physical events that occur during the freezing process (hexagomers represent ice 
crytals). Slow cooling rates resulted in cell dehydration, while rapid cooling rates cause cell damage. Conditions 
for an optimal cooling rate are unknown but it is believe to be a rapid cooling rate without formation of ice crystals. 
Representative diagram from P. Mazur [5]). 
 
During slow freezing water is diffused out of cells by a process called exosmosis, resulting in 
an increase in extracellular ice formation. Meanwhile inside the cell, solute concentrations 





inhibited and the possibility of intracellular ice formation increases causing destruction of the 
cell membranes. 
Intracellular ice is the main mediator of cryo-induced damage. Ice formation results in 
the rupture of cellular membranes leading to cell death, however re-crystallization during the 
warming process (thawing) is also a cause of cellular damage. There is evidence that 
intracellular ice can be propagate between cells [8]. The more times that the cells are in 
close contact with each other, the greater the propagation of ice [9, 10]. Additionally, 
extracellular ice that is present can facilitate the formation of intracellular ice [5, 11, 12]. 
Most of the cryopreserved cells are kept at -196°C for long-term storage and at this 
temperature biological processes are ceased. Improper cryopreservation can lead to a chain 
of events in which metabolic processes are altered by way of changes in membrane 
composition due to chilling injury [13-17]). Examples of events following damage to the 
membranes are: i. activation of apoptosis and calcium dependent phosphatases [6, 18-20], ii. 
activation and release of lysosomal and lipoprotein hydrolase [21, 22], iii. release of free fatty 
acids [23], iv. disruption of the cytoskeletal structure [24-27], and v. activation of apoptotic 
cascades [6]. Very slow freezing can result in toxicity effects due to concentration of solutes 
within the cell that result in delayed necrosis and apoptosis [6].   
 
2.1.3 Cryopreservation freezing methods 
In cryopreservation there exist various methods to cryopreserve cells either by vitrification, 
computer-controlled rate freezing, or by conventional methods (isopropyl alcohol bath based 
container Nalgene Mr. Frosty).  
Vitrification is defined as a process wherein a liquid solution or substance is converted into a 
glassy state (vitreous state) due to rapid cooling through the glass transition of the substance 
[28]. Importantly, this rapid cooling can avoid the formation of ice crystal. There are several 
ways to accomplish vitrification by using open pulled straw, cryoloop or cryo-electron 
microscopy in combination with a cryoprotectant agent (CPA). Vitrification is mainly used for 
the cryopreservation of mammalian embryos, but is mostly used for oocytes [29, 30]. The 
main limitation of vitrification is that it requires high cooling rates and high CPA 
concentrations [31, 32].  
The conventional method (CM) is commonly used in laboratories as a method for the 
cryopreservation of cells. It provides a cooling rate of 1°C/min. CM is easy to perform, cost-
effective and requires low concentrations of CPA [33]. The conventional method has 3 
disadvantages: a. rapid cooling, more than 1°C/min is difficult to reach, b. freezing is limited 
to -80°C and c. the procedure needs an overnight incubation at -80°C.  
The use of controlled rate freezing allows the creation of specific temperature profiles for 
specific cell types along with specific cryoprotectant agents in order to optimize cell viability 
and recovery [34, 35]. By controlling the cooling rate, the prevention of intracellular ice 
formation is accomplished [34]. Freezing temperatures of either the chamber or sample can 
be controlled to match the time profiles. The benefit of using controlled rate freezing is that it 
can be applied to most compliance standards (GMP- and GLP-based) since the device and 
software records each freezing event (Fig 5) and optimizations of freezing protocols are easy 




















Figure 5. Schematic representation of recorded controlled rate freezing program for GLP/GMP standards where 
cooling rate of the sample, freezer and program are obtained for every independent freezing process.  
 
The advantage of using controlled rate freezing is the low requirement of cryoprotectant 
concentrations which are needed to accomplish intracellular freezing thereby reducing the 
toxicity effects of the cryoprotectant [33]. On the other hand, controlled rate freezing is time 
consuming and requires expensive equipment.  
 
2.2 Cryoprotectant Agents 
In order to protect cells and tissues during the cryopreservation procedure a cryoprotectant 
agent (CPA) is used. CPA is a substance use to minimize damage during freezing by 
increasing the solute concentration in the cell. A good CPA should be non-toxic, be able to 
permeate the cell membrane, have a low molecular weight, and avoid solution effects as well 
as osmotic shock. There are two types of CPA: permeating (e.g., DMSO, propylene glycol, 
glycerol) and non-permeating (e.g., sucrose, trehalose, hydroxyethyl starch). Permeating 
CPAs are able i. to form hydrogen bonds with water molecules thereby preventing ice 
crystallization, ii. at low concentrations, to decrease the freezing temperature and at high 
concentrations to inhibit the formation of intracellular ice crystals, iii. to cause electrolyte 
concentrations to increase at a certain temperature during the freezing process and, iv. to 
increase the final size of the cells [2]. On the other hand, non-permeating CPAs are often of 
a high molecular weight, provide extracellular protection and prevent osmotic shock. A 
disadvantage of using penetrating CPAs is that prolonged exposure can be toxic to the cells 
due to disruption of intracellular signaling [36] therefore removal after thawing is necessary. 
 
2.2.1 Dimethylsulfoxide (DMSO – C2H6OS) 
DMSO belongs to the group of small MW penetrating CPAs. It is an amphiphilic molecule 
with two hydrophobic methyl groups and a hydrophilic sulfoxide group [37, 38]. DMSO 
cryoprotectant properties were first reported in 1959 for the preservation of red blood cells 
[39]. DMSO acts as a CPA through a preferential exclusion mechanism by increasing the 
freeze energy of unfolding and stabilizing cellular proteins [40] and by interacting 
electrotrastically with phospholipid bilayers thereby stabilizing the plasma membranes [41]. 
However, DMSO is also known to cause denaturation and destruction of proteins by 





DMSO has several other biological functions such as being an inducer of cell fusion, 
increasing cell permeability and promoting cell differentiation [41, 44-46].  
 
2.2.2 Fetal Bovine Serum (FBS) 
FBS is commonly used as a CPA in combination with DMSO in many research laboratories 
since it supports good cell recovery. FBS contents are unknown but it is clear that its 
composition provides cryoprotective effects by stabilizing biomembranes and by balancing 
osmotic pressure [35, 39, 47, 48]. A big disadvantage of using FBS as a CPA results from its 
composition being unknown therefore animal product contamination with viral or prion 
diseases, or xenogeneic immune responses may be possible [49].  
 
2.2.3 Sugars 
The concept of sugars as CPAs was introduced in the 1900s by Maximov as protective 
agents were observed to induce a natural freeze tolerance in plants [50]. In nature sugars 
like glucose, sucrose and trehalose are used by many organism, e.g. frogs [51], bacteria 
[52], brine shrimps [53], yeast [52] and plants [54] to resist  extreme freezing conditions [55, 
56]. Accumulation of intracellular and extracellular sugars is required for their survival [55]. 
The protective effects of sugars were also determined in liposomes, membranes and 
proteins in freeze-drying cryopreservation [57, 58]. Sugars have been used as CPA since 
they are non-toxic and act by protecting proteins and cell membranes [58-60]. The 
advantages of using sugars for cryopreservation is due to their high glass transition 
temperature allowing for long term storage of cells [61, 62], but complex sugars (e.g. 
dissacharides - trehalose) are impermeable to mammalian cells membrane due to the 
presence of hydrophilic residues or the lack of active transport system [63, 64]. Trehalose is 
the most common sugar used as extracellular CPA in cryopreservation since it can interact 
more strongly with water molecules [53, 59, 60, 65], and it protects cell membranes [55] and 
membrane vesicles [66, 67]. Efforts have been performed to introduce trehalose into cells by 
different mechanisms in order to enhance survival rates\recovery after cryopreservation [68-
71]. 
In addition to trehalose, glucose is another common extracellular CPA often used in 
combination with intracellular CPA [72-76]. Glucose is a simple monosaccharide, the primary 
energy source of cells, and is involved in many biochemical pathways and mechanisms of 
action. In cryopreservation the mechanism of glucose protection is mediated by its binding to 
proteins and lipids and stabilization of membranes [77, 78]. At higher concentrations, 
however, glucose causes toxicity by its osmotic effects [79]. In addition, protein glycations 
are more likely to occur in presence of glucose. Glycation of proteins interfere with enzyme 
activities, membrane stability and promote the formation of reactive oxygen species [80-84].  
 
2.2.3.1 Sorbitol (C6H14O6) 
Polyalcohols are defined as alcohol that contains more than one hydroxyl group. They show 
cryoprotective effects for the cryopreservation of oocytes and embryos [85] and human 
erythrocytes [86]. Sorbitol is a sugar alcohol which can be obtained by reduction of glucose 
and an organic osmolyte that is known to have protective activities during cryopreservation 
by preventing osmotic cell damage [86]. There is no real evidence as to whether sorbitol is 







2.2.3.2 Dextran (H(C6H10O5)xOH) 
Dextran belongs to the high molecular CPAs that were first used in 1947 in clinical settings 
as a plasma expander [89-92]. It has shown cryoprotective functions for different cell types 
[93, 94]. Given its high molecular weight (MW) dextran acts by i. increasing the solution 
viscosity, ii. reduction of the cooling rate for optimal survival during the vitrification process, 
iii. increasing the predisposition of supercooling and iv. inhibiting ice formation  [95, 96]. 
 
2.2.4 Hydroxyethyl starch 
Hydroxylethyl starch (HES) is a synthetic modified polymer of amylopectin (highly branched 
polymer of glucose) based on purified starch from corn or potato that has been modified by 
hydroxyethylation at carbon position C2, C3 or C6 [90-92]. This hydroxyethylation process 
increases HES solubility and affinity with water.  The physical and chemical properties of 
HES depend: i) in the manufactured MW, ii) degree of molar substitution (MS, total number 
of hydroxylethyl group present per total glucose subunit), iii) the C2/C6 ratio (the 
hydroxyethylation at carbon position C2 and C6), and iv) the mean molecular weight.  HES 
molecular weight is classified based on the manufacturing and it ranges from high MW ≥ 450 
kDa, medium MW 200-400 kDa, and low MW < 200 kDa [97]. The molar substitution (MS) 
and C2/C6 determine HES hydrolysis rate therefore the higher the molar substation and the 
C2/C6 ratio, the slower the breakdown rate of HES.   
In vivo, HES is metabolized by alpha amylase or excreted in urine. Αlpha-amylase is a 
calcium metalloenzyme that cleaves complex starch into sugars (maltose and dextrin). The 
rate of breakdown of HES is dependent on its molecular weight; high and medium MW HES 
breakdown into a wide range of HES fragments and lower MW HES is excreted in urine. The 
resulting HES fragments, however, are the ones that determine HES function, activity, and 
the secretion rate.   
The advantages of using HES in the cryopreservation process are non-toxicity, poor 
antigenicity and the ability to absorb water molecules [97-99]. The mechanism of HES 
cryoprotection is different from that of commonly used penetrating cryoprotectors such as 
DMSO and glycerol which are known to depress the freezing point of solution and delay 
damaging salt concentrations to lower temperatures. In contrast the cryoprotective effect of 
HES depends on its ability to absorb water molecules and keep them thermally inert in a 
glassy state without experiencing any phase transition during cooling. Accumulation of HES 
in extracellular space leads to dehydration of cells during cooling at high sub-freezing 
temperatures and allows them to be cooled rapidly thereby avoiding intracellular ice crystal 
formation and osmotic stress, as well as chilling injury which can occur during the process of 
slow cooling and can lead to serious damage [96, 100, 101]. During warming the high 
intracellular viscosity suppresses intracellular ice crystal growth and helps overcome the 
problem that occurs during devitrification – ice crystals growing when the temperature in 
samples rises slowly to -60°C and above. 
 
2.3 Cell banking of skin cells and mesenchymal stem cells 
2.3.1 Skin cell types: fibroblasts and keratinocytes 
The skin is the largest organ of the human body and its main role is to maintain the stability 
of the body’s internal milieu and to separate the internal environment from the external. It has 
various functions such as providing protection from biological invasions, as well as from UV 





sensations, the excretion of salt and waste, and the production of vitamin D [102, 103].  The 
skin is composed of 3 layers: epidermis, dermis and hypodermis. 
2.3.1.1 Fibroblasts 
Fibroblasts are mesodermal in origin and are the main cells of the dermis. These cells are 
able to produce extracellular matrix and collagen. They are the most common cell type of the 
connective tissue in animals and play an essential role in wound healing.  Fibroblasts show 
mesenchymal phenotypes and can be characterized based on marker expression such as 
vimentin, FSP, SMA-α, or lack of colony-forming capacity and inability to differentiate into 
other cell types [104].  
2.3.1.2 Keratinocytes 
Keratinocytes have an ectodermal origin and play an essential role in the skin anatomy 
(epidermis). They emerge from the epidermal stem cells through a controlled differentiation 
process in which the differentiated cells are dead thereby forming the skin surface [105-107]. 
Keratinocytes have physical and immunological functions, and mostly cultured today using 
optimized keratinocyte media. Under these conditions keratinocyte viability is decreased and 
a stage of advanced differentiation is observed [108, 109]. Therefore, optimization of 
cryopreservation protocols are commonly performed using keratinocyte cell lines since no 
requirement of feeder cells and extended life span make them a great model for the 
determination of cooling rates and cryoprotectants [110, 111]. 
2.3.1.3 Skin tissue-engineered fibroblasts and keratinocytes 
Skin substitutes are commonly used as tissue replacement for the treatment of wounds and 
burns. In most cases it does not require tissues and/or cells from the donor and improvement 
of the healing process can be observed [112]. The end result of tissue-engineered skin is the 
production of skin by either mainly using cells, only the extracellular matrix materials or a 
combination of both [113, 114]. In addition, tissue-engineered skin has been used for the 
testing of drugs and other agents thereby replacing the use of animals [115-117]. 
Dermal fibroblast and keratinocyte cells are commonly used as skin substitutes for the 
treatment of skin-related problems such as wounds, ulcers and burns. Both autologous or 
allogeneic fibroblasts and keratinocytes can be used for transplantation. Allogeneic 
fibroblasts can be used for pre-conditioning the wound bed prior to implantation [118]. 
Phillips et al proposed that cultivation of fibroblasts and keratinocytes in vitro reduce the 
likelihood of having any type of rejection because Langerhans cells, antigen-presenting cells, 
are lost during the cultivation procedure [119].    
Optimization of tissue-engineered skin substitute is necessary since long-term storage might 
result in a decrease in the viability of the cells. Cryopreservation of skin substitutes might 
have adverse effects after implantation since stress proteins and a stress reaction can occur 
during the cryopreservation process [120]. Therefore, suboptimal cryopreservation protocols 
and solutions are on high demand. 
 
2.3.2 Mesenchymal stem cells  
Mesenchymal stem cells (MSC) are non-hematopoietic stem cells with multi-lineage potential 
which have a mesoderm origin. These cells were firstly isolated from the bone marrow by 
Friedenstein in 1976 [121].  However, recently MSCs have been reported, among others, in 
adipose tissue, umbilical cord blood and tissue, and placental and peripheral blood. MSCs 
have the ability to differentiate into different cell types, among others: osteoblast (bone), 
adipocytes (fat) and chondrocytes (cartilage). MSC characterization is based on the 





negative: CD45, CD34, CD11b or CD14, CD79α or CD19), adherence to plastic and in vitro 
differentiation [122]. Also, MSCs lack expression of immunohistocompatibility complex II 
(MHC-II) and co-stimulatory molecules making them immunosuppressive. Since MSCs can 
be expanded ex-vivo showing similar functionality as in-vivo they are a very great source for 
autologous and allogeneic cell therapies for the treatment of injuries or age –related diseases 
[123-125].  
2.3.2.1 MSCs in regenerative medicine 
Since MSCs are multipotent cells and induce non-immune response after transplantation it 
makes them a very promising tool in the field of regenerative medicine. MSCs have been 
successfully used in the treatment of spinal cord injury [126] cartilage lesions [127] and bone 
defects [128]. In addition, clinical trials using MSCs for the treatment of cirrhosis, graft-
versus-host disease, left ventricular dysfunction, osteogenesis imperfecta, metachromic 
leukodystrophy and Hurley syndrome [129, 130] are in process. MSCs are currently used as 
substitute in autologous bone marrow transplantation [131]. 
It is known that MSCs have a limited lifespan in culture (population doubling time 15-50) 
[132] and with increases in passages a decrease in their proliferative capacity and 
differentiation is observed [133-137]. In addition, a correlation was observed between low cell 
recoveries of cryopreserved MSCs and poor in vivo differentiation [131] indicating the need 
to improve cryopreservation protocols for MSCs. Therefore, MSCs banking is necessary to 
control batch variations and quality control to ensure its use in research and clinical 
application in stem cell-based therapy.  
 
2.4 Cryopreservation of fibroblasts, keratinocytes and 
mesenchymal stem cells 
2.4.1 Fibroblasts cryopreservation  
Since fibroblasts are used as dermal substitutes in skin tissue engineering, several attempts 
have been performed for the optimization of fibroblast cryopreservation by different cooling 
rates and/or cryoprotectant agents.  Table III summarizes relevant data regarding human 
fibroblast cryopreservation in suspension and adherent comparing freezing protocols and 
CPAs. 
 
Cell Type Method Freezing Protocol CPA 
Primary Fibroblast [111] Suspension 1°C/min DMSO 
Primary Fibroblast in  
collagen gel [138] 
Suspension 0.5°C/min  from   20°C -70°C-
5°C/min from -70°C to-170°C 
DMSO 
Dermal Fibroblast [139] Suspension 1°C/min -80°C N2 tank  
Lung Fibroblast [140] Suspension 3°C/min from RT to 4C 
4C for 5 min 
1C/min from 4C to -50C 
5C/min from -50C to -80C  
 N2 tank 
DMSO + 
serum 
I-cell disease fibroblast 
[141] 




Dermal Fibroblast [142] Suspension ~2.4°C/min in -80°C freezer D-allose 
Dermal Skin Fibroblast  
Slices [143] 







Dermal Fibroblast in  
PGA Scaffold [143] 
Adherent 0.5°C/min     -4°C to -60°C   
1°C/min              N2 tank 
DMSO 
Dermal Fibroblast [144] Adherent 3°C/min from 4 to -80°C  -
cooled to 185°C 
Hyalouronan 
 
Table I. Overview of cooling rates and cryoprotectants for human fibroblast cryopreservation 
In most of the experiments for fibroblast cryopreservation, non-permeable sugars and DMSO 
(among others) were used in order to enhance cell recovery during the cryopreservation 
procedure. Incubations with different concentrations of DMSO, temperatures, and time 
showed that toxicity and viability is dependent on the temperature and exposure time [143].   
A study performed by Choi et al showed a correlation between cooling rate, intracellular ice 
formation and fibroblast viability [145]. In addition, differences between suspension and 
adherent cryopreservation based on cooling rates were observed. Fibroblasts 
cryopreservation in suspension was possible using a fast cooling rate and as adherent with a 
slow cooling rate.  This result contradicts what previously was shown by others wherein slow 
cooling resulted in higher cell viability compared to a medium cooling rate and vitrification.  
In addition, there is not a complete study in which different freezing protocols were compared 
to determine whether the same cryopreservation protocols can be applied to primary 
fibroblasts and fibroblast cell lines. 
  
2.4.2 Keratinocytes cryopreservation 
In parallel to fibroblasts, keratinocyte cryopreservation is also frequently optimized due to its 
role in skin-tissue engineering for dermal replacement. A wide range of studies are available 
wherein keratinocytes were cryopreserved in suspension and adherent and in absence of 
DMSO.  Table IV compiles data available in cryopreservation of human keratinocytes.  
 
Cell Type Method Freezing Protocol CPA 
Primary Keratinocyte [146] Suspension -3°C/min HES 
Primary Keratinocyte [147] Suspension -3.5°C/min HES 
Freshly isolated and primary 
cultured keratinocytes [148] 
Suspension -1C/min in -20C freezer x  





Primary Keratinocyte [149] Suspension -1°C/min DMSO 






HaCaT [142] Suspension ~2.4°C/min in -80°C freezer D-allose 
Primary Keratinocyte [69] Suspension 1°C/min from -6°C to -15°C  
hold 20min  N2 tank 
Poration 
trehalose 




Primary Keratinocyte [146]  Adherent 3.3°C/min in -85°C freezer - 
HaCaT cell line [110] Adherent Styrofoam box in -70°C  DMSO 
 
Table II. Overview of cooling rates and cryoprotectants for human keratinocyte cryopreservation 
 
In addition, keratinocyte cryopreservation encounters a major problem which is that of cell 





and not described or deviations not reported. Therefore, it is crucial to study the 
cryopreservation process in more detail and to improve it in a reliable way.  
 
2.4.3 Mesenchymal stem cell cryopreservation 
MSCs are frequently used in regenerative medicine as stem cell-based therapy. It is known 
that cryopreservation affects MSC behavior and functionality.  
One main problem in MSC cryopreservation is the use of DMSO as a CPA since it has 
shown adverse effects in hematopoietic stem cell therapy. Various attempts on MSC 
cryopreservation have been performed to either eliminate or reduce DMSO concentration by 
combining it with other CPAs [151].  
Cryopreservation protocols and CPA used for the cryopreservation of MSCs from different 
sources were exemplified in Table V.  
 
Origin Method Freezing Protocol CPA 
Umbilical cord 
[152] 




Suspension 2°C/min from RT to 0°C  
1°C/min to -40°C  5°C/min -
40°C to -80°C 




Suspension 4°C for 10 min  Mr. Frosty 
(1°C/min) to -80°C for 24hr  N2 
tank 
DMSO + PEG + albumin 
Bone Marrow 
[155] 
Suspension 4°C for 10min  -30°C for 1h  -
80°C for 2-3 days  N2 tank 
DMSO + serum + 
Cell Bank Solution 
Bone Marrow 
[156] 
Suspension Directly in N2 tank DMSO + HES 
Bone marrow 
[157] 
Suspension 4°C for 1 h  1°C/min to -40°C  
10°C/min from -40°C to -70°C 
N2 tank 
DMSO + serum 
Bone Marrow 
[158] 
Adherent 4°C for 15 min  1°C/min, 
5°C/min or 10°C/min 
DMSO + serum 
Adipose 
[159] 
Suspension 0,5°C/min from 4 to -20°C  -
80°C freezer for 24h  -196°C for 
2 weeks 
DMSO + serum 
 
Table III. Overview of cooling rates and cryoprotectants in mesenchymal stem cell cryopreservation 
 
As a result of CPA toxicity and the decrease in differentiation potential, optimization of MSC 
cryopreservation is necessary for its use in a clinical setting and cell banking.  
 
2.5 Aims of the study 
 
Cryopreservation of cells can be accomplished at temperatures below 0°C. The mechanism 
of cryopreservation is not well understood therefore accomplishment of the perfect 
cryopreservation method is difficult. Optimization and creation of freezing protocols and 
cryoprotectants are on demand. Two major problems in the cryopreservation field are the 





reduce cryo-injury but toxicity is usually encountered. Therefore, combination of an 
appropriate cryoprotectant (s) and cooling rate(s) can result in a successful cryopreservation 
protocol.  
The first aim of this study is to improve cryopreservation of mesenchymal stem cells by 
comparing the effect of cooling rates and DMSO substitution with hydroxyethyl starch. It is 
widely known that DMSO results in cell toxicity and adverse effects have been observed after 
intravenous injection of cryopreserved red blood cells with DMSO. Since MSC are used as 
cell-based therapy, cryopreserved rat MSCs under different conditions were analyzed after 
thawing based on stemness (differentiation potential and phenotyping), cell viability and 
recovery.  
The findings obtained by the cryopreservation of rat MSC lead to the following study wherein 
combinations of sugars and hydroxyethyl starch were used as cryoprotectants for the 
cryopreservation of umbilical-cord MSCs. In this study, the use of DMSO as well as serum 
were completely omitted, serum being an animal product and contamination with virus 
agents being possible. Differentiation potential, morphology and viability were analyzed after 
cryopreservation of UC-MSC using sorbitol, dextran and HES combinations as CPAs.  
 
The second aim of the study presented here was to perform a comparison of cooling rates 
and cryopreservation of cells in suspension versus adherence. As cell types, tissue 
engineering skin cells, fibroblasts and keratinocytes, were used for the studies. In addition, 
comparison between primary cells and cell lines performed. These cells are used as dermal 
replacement in the treatment of skin-related conditions. Cryopreservation protocols are 
constantly optimize for these cells but the main limitation presented in most of the studies is 
the lack of a full comparison of different freezing protocols and suspension versus adherent 
cryopreservation. Therefore, the purpose of this study was to take in consideration all these 
factors and to compare the obtained results with published data. Cell viability, recovery and 
cell morphology were analyzed after cryopreservation. In addition comparison of the different 
freezing protocols was performed as well as cryopreservation of the cells in suspension 
versus adherence. 





3  Overview of the introduced manuscripts 
 
Published manuscripts  
 
1. Hydroxyethylstarch in cryopreservation – Mechanism, benefits and problems 
 
Alexandra Stolzing, Yahaira Naaldijk, Viktoriya Fedorova and Sebastian Sethe 
Transfusion and Apheresis Science, 2012, 46: 137-147 
 
Summary: This review discusses relevant information about hydroxyethyl starch and its 
cryoprotective benefits in the cryopreservation of cells, mainly stem cells. A detailed 
comparison of published data on HES and cryopreservation was performed and described 
on the paper.    
 
Author Contributions:  
AS: design of figure 1-3, writing of subsections and provide the idea for the manuscript.YN: 
writing of subsections and tables. VF: writing of subsections and tables. SS: wiriting of 
subsections and revision of the manuscripted 
 
2. Effect of different frezing rates during cryopreservation of rat mesenchymal 
stem cells using combinations of hydroxyethyl starch and dimethylsulfoxide 
 
Yahaira Naaldijk, Marek Staude, Viktoriya Fedorova and Alexandra Stolzing 
BMC Biotechnology, 2012, 12(49): 1-10 
 
Summary: The purpose of this study was to compare different cooling rate in combination 
with different HES-based solutions in order to substitute and/or minimize DMSO 
concentration from the cryosolution without interfering with MSC stemness and viability.  
 
Author Contributions:  
YN: designing of the freezing protocols, chrondrocyte differentiation, flow cytometry data for 
CD44 and CD11b, freezing curves figure, consolidation of the data and provided the 1st draft 
manuscript 
MS: cryopreservation experiments, viability experiments and differentiation of the cells 
towards osteogeneic and adipogenic differentiation. In addition, flow cytometry data for CD90 
and CD45 and morphology pictures 
VF: help with flow cytometry stainings for CD44 and CD11b and contribution in writing the 
paper 




3. Comparison of different cooling rates for fibroblast and keratinocytes 
cryopreservation 
 
Yahaira Naaldijk, Annett Friedrich-Stöckigt, Sebastian Sethe and Alexandra Stolzing 
 




Summary: The manuscript compares different freezing protocols for the cryopreservation of 
fibroblasts and keratinocytes in suspension as well as in adherent. The paper demonstrated 
differences in freezing protocols for the cryopreservation of cells, either in suspension or 
adherent, and cell type dependent.   
 
Author Contributions:  
YN: planned and performed the experiments, analyzed the data and wrote the 1st draft of the 
manuscript 
AF-S: provided technical support with the experiments and cell culture. 
SS: provided help on data interpretation and revision of the manuscript 
AS: planned the experiments, secured the funding and revised the manuscript, and was 
responsible for the project.  
 
Publication status: Under the second revision by Journal of Tissue Engineering and 
Regenerative Medicine 
 
4. Cryopreservation of human umbilical cord-derived mesenchymal stem cells in 
complex sugar based cryoprotective solutions 
 
Yahaira Naaldijk, Viktoriya Fedorova and Alexandra Stolzing 
 
Summary: The manuscript accentuate the use of use of sugars and HES for the 
cryopreservation of human umbilical cord blood MSC using in which differentiation into bone, 
adipose and chondrocyte were not affected after cryopreservation. This paper provides with 
a novel cryosolution based on sorbitol, dextran and HES without having the adverse effect 
and toxicity of DMSO solution.  
 
Author Contributions:  
YN: performed experiments, consolidated the data and revised and help in manuscript 
writing 
VF: planned and performed experiments and wrote the 1st draft of the manuscript 
AS: planned the experiments, secured the funding, arranged the tissue collections and 
revised the final version of the manuscript. 
 























































































4.2 Effect of different frezing rates during cryopreservation of rat mesenchymal stem 
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Supplemenraty Figure 3 
 






















































































4.4 Cryopreservation of human umbilical cord-derived mesenchymal stem cells in 



























The development of an effective cryopreservation protocol without the loss of cell 
functionality, viability and differentiation is a critical requirement for the application of tissue 
engineering and cell-based technologies which are required for further clinical applications.  
In most situations cryopreservation involves the addition of cytotoxic and xenogenous 
compounds in order to enhance effectiveness. The long-term cryogenic storage of cells and 
tissue is not very well investigated nor adopted for different products. The use of alternative 
cryosolutions and the titration of DMSO concentration have been investigated in many 
different cell types with various degrees of success.  
The studies presented in this thesis emphasize the reduction of DMSO from the cryosolution 
and the use of alternative non-toxic cryoprotectant agents such as sugars and starches for 
mesenchymal stem cell cryopreservation. In addition, we showed a complete comparison of 
3 freezing methods: controlled rate freezing, vitrification and the use of an isopropanol-based 
freezing container. No data is available where these methods were fully compared for the 
cryopreservation of fibroblasts and keratinocytes in suspension and as adherent cells, and to 
some extent for mesenchymal stem cells.   
 
5.1 Sugars and starches as substitute for DMSO in the 
cryoprotectant solution 
5.1.1 DMSO in cryopreservation 
DMSO is extensively used as a cryoprotectant agent since favorable cryopreservation is 
mostly achieved with high standards for cell recovery after thawing. During the 
cryopreservation process DMSO diffuses into the cells, maintaining osmotic balance and 
replacing water and reducing the formation of intracellular ice. 
The use of DMSO as a cryoprotectant or solvent has negative side-effects at the biological 
and clinical levels. DMSO can decrease membrane thickening and induces temporary water 
pore formation when used at lower concentrations. At higher concentrations it induces 
disintegration of the bilayer structure of the lipid membrane [37]. At the cellular level, DMSO 
induces changes in morphology, adhesion, growth, cytoskeleton distribution, decreases the 
number of stress fibers and can cause apoptosis [160-166].  
In human embryonic stem cells, exposure to DMSO diminishes stemness and differentiation 
potential [167, 168] while their cryopreservation with DMSO reduces the expression of Oct-4, 
a pluripotent marker [169]. Similar results were obtained for human pluripotent stem cells 
where exposure to DMSO reduces plating efficiency [170]. 
In the clinical setting, the effect of DMSO in topical application has been tested as well as in 
transplantation. In vivo, DMSO acts as a histamine releaser. Application of DMSO into 
human skin causes whealing, swelling, erythema, a strong garlic taste in the mouth and 
pruritus, among other effects [171-173]. Long-term exposure of DMSO affects the cyclic AMP 
(cAMP) system in epidermal keratinocytes in pig skin dermis [174] and degeneration and 
disintegration of the epidermis [175].  
At the moment skin tissue, red blood cells and hematopoietic progenitor cells are stored 
using dimethyl sulfoxide, which can cause severe side-effects in patients such as 
neurological damage, gastroinstestinal problems and loss of consciousness, among others 





of the cells meaning loss of time and cells which are important as only low amounts of stem 
cell are available. 
Given that DMSO has various adverse effects, it is important to have a DMSO-free 
cryosolutions for the cryopreservation of cells. As substitutes for DMSO, sugars and starch 
can be used as cryoprotectants. They are not toxic to cells and can protect the cell 
membranes thereby providing an alternative or addition to classical cryopreservation 
solutions. Combinations of sugars and low concentration of DMSO have been shown to be 
successful in the cryopreservation of mouse oocytes [180], hematopoietic stem cells isolated 
from umbilical cord [181], and human fetal liver hematopoietic stem/progenitor stem cells 
[182]. 
Therefore, reduction or elimination of DMSO from the cryosolution is necessary. Data 
presented in this dissertation clearly demonstrate that DMSO can be substituted by sugars 
and starches in the cryopreservation of mesenchymal stem cells as describe in the sections 
below.  
 
5.1.2 Hydroxyethyl starch in the cryopreservation of mesenchymal stem cells 
HES is widely applied in the clinical setting as a plasma volume expander due to its colloidal 
osmotic pressure to allow delivery of oxygen by red blood cells, in hemodilution treatment to 
enhance microcirculation, and for peripheral arterial stenosis treatment [97]. Since serious 
side-effects are not often reported and are less harmful compared to others plasma 
expander, pruritus (itching) is known to occur after intravenous HES administration. The 
reason for the development of pruritus is not clear but recent publications suggest that 
uptake of HES by mononuclear cells, keratinocytes, and Langerhans cells, among other 
cells, are responsible for the itching effect observed after HES administration, as seen by 
biopsy specimens and by in vitro studies [183-187].  
Autologous re-infusion of cryopreserved red blood cells showed that HES is nontoxic and is 
safe in clinical practice. No adverse reactions after reinfusion of cryopreserved RBC with or 
without post-thaw washing step were observed.[188].  
It was shown that successful non-penetrating cryoprotectors such as Ficoll, PVP and dextran 
have glass-transition temperature (Tg) around -20°C and 20% HES solution which allows 
successful cryopreservation of human monocytes also has a Tg close to -20°C [101]. At 
temperatures lower than -20° C, the formation of glass avoids further osmotic stress and 
cells are isolated from the extracellular ice reducing water loss by the cells [101].  
There are several publications that illustrate the use of HES in cell cryopreservation [146, 
150, 189-195]. It is suggested that HES protects by reducing the intracellular ice formation 
since HES limits crystal growth [99, 100, 196]. HES has been used to preserve keratinocytes 
[146, 150], human islets [197], red blood cells [191], and human peripheral blood stem cells 
[195, 198], among others. The addition of HES to the cryoprotectants solution increases the 
recovery and viability rate after freezing [146]. Moreover, Singbartl et al showed that 
cryopreservation of human erythrocytes using HES resulted in transient rheological 
alterations in patients after transplantations [199]. Therefore, like any other cryoprotectants, 
the effectiveness of HES in cryopreservation might depend on the used freezing protocols, 
techniques and materials, as well as on cell type.  
5.1.2.1 HES as an alternative to DMSO in MSC cryopreservation 
Since HES is a good candidate and possibly reduction of DMSO concentration from the 





after mesenchymal stem cell cryopreservation with different molecular weight of HES and 
titration of HES: DMSO ratio.  
DMSO was substituted with HES 450 –molecular weight of 450 kDa - showing no negative 
effect on MSCs CD markers – CD90 and CD44 – and on cell viability (more than 85%) after 
thawing. In prolonged cultures of cryopreserved MSC, CD phenotype does not change in 
agreement with previous findings by others [200, 201] but cell viability is dramatically 
reduced at day 3. The decrease in cell recovery suggests that a penetrating cryoprotectant, 
e.g. DMSO, is still necessary for survival. HES is known to be a non-penetrating 
cryoprotectant and there is no evidence whether MSCs are able to uptake HES by 
pinocytosis like other cell types [187].In addition, a decrease in cell viability can be 
interpreted as cryo-injury due to formation of intracellular ice crystals during the freezing or 
thawing process, osmotic changes or apoptosis. Cell death and necrosis associated with 
cryopreservation after 24 hours of thawing have been shown previously [202-204] which can 
explain the reduced viability. Given this, determination of cell viability after thawing cannot 
represent reliable criteria for estimation of cryopreservation efficacy.  
The cell viability of cryopreserved MSC was dependent on DMSO:HES 450 concentration. 
Reduction of DMSO concentration lower than 4% showed detrimental cell recovery since 
less intracellular cryoprotection is available increasing the likelihood of cellular damage. Ginis 
et al reported reduced cell viability for cryopreserved BM-MSC with 2% DMSO compared to 
5% and 10% DMSO [205]. 
Analysis of stemness after cryopreservation showed that osteogenic differentiation is 
DMSO dose-dependent. At higher DMSO concentrations, reciprocal HES 450 
concentration decreases, and slight reduction in ostegenic capacity was observed for 
cryopreserved MSC. DMSO is known to affect differentiation of stem cells by altering 
the gene expression [169, 170, 206] but some publications have found no differences 
in osteogenic differentiation after cryopreservation with 5% and 10% DMSO [155, 
207, 208], but only for 20% DMSO [208]. In addition, cryopreserved embryonic stem 
cells with DMSO tend to differentiate immediately after been thawed [209].  
Findings, including our own, on stem cells might indicate that stress induced during 
cryopreservation and/or DMSO toxicity interferes with the differentiation capacity of 
MSCs. It is know that differentiation of ESC is affected by oxidative stress [210] and 
impaired differentiation of endothelial progenitor cells was observed after 
cryopreservation due to an increase in cell death [211]. Therefore, stress induced by 
cryopreservation seems play an essential role in balancing the survival and 
differentiation of the cells. 
To summarize the findings discussed in this section partial replacement of DMSO by 
HES 450 for mesenchymal stem cells cryopreservation is admissible. Differentiation 
potential of MSC is affected by DMSO concentration but the use of solely HES 
clearly showed an improvement in differentiation potential. Viability is dependent on 
DMSO since HES by itself cannot sustain cell recovery after cryopreservation.  
In conclusion, if viability is required then partial reduction of DMSO is possible but if 
differentiation potential is the main goal HES alone can be used; however, it will 
require a higher number of cryopreserved cells to compensate for the cell loss after 
thawing.   





In the cryopreservation field, different molecular weights of HES have been used 
ranging from 150 to 450 kDa [146, 150, 190, 191, 212] making it difficult to determine 
whether HES MW has an effect as a cryoprotectant. Different MW ranging from 109 
to 609 kDa with the same molar substitution were tested in MSC cryopreservation in 
absence of DMSO. HES molecular weight does not have an effect on differentiation 
and cell viability within the different HES MW. Cell viability was lower compared to 
DMSO indicating that HES alone does not support cryopreservation of MSCs. Our 
findings contradict Pasch et al which found that cryopreservation of keratinocytes 
result in viability around 80% for HES alone [146]. We must take in consideration that 
Pasch findings consist of higher standard deviations indicating great variations within 
the experiments probably due to HES viscosity or cell death associated to the 
freezing/thawing process. 
In summary, HES molecular weight has no effect on cryopreservation efficiency for 
mesenchymal stem cells but the question of whether different molar substitutions on 
HES can decrease or increase the quality of the cryopreserved cells must be 
investigated.  
In conclusion if viability and stemness are both necessary for MSC cryopreservation 
a solution based on 6:5 (HES:DMSO) can be used. It was shown by others that 
cryopreservation of bone marrow and stem cells with 6% HES & 5% DMSO provides 
successful cryopreservation [192, 198, 212, 213]. At 6% HES the viscosity in the 
extracellular environment of the cell increases and the diffusion capability decreases 
reducing shrinkage of the cells during the cooling process decreasing ice 
formation.[96, 100, 101].  
 
5.1.3 Cryosolutions based on dextran, sorbitol and hydroxyethyl starch in the 
cryopreservation of mesenchymal stem cells 
In nature, survival of certain animals such as frogs in cold temperature is based on the 
accumulation of sugars in their bodies indicating that sugars can act as CPA. 
Sugars have a high glass transition temperature compared to DMSO which makes sugars a 
good candidate for cryopreservation. It was shown that cryopreservation of oocytes [180], 
cornea endothelial cells [214], and several cancer cell lines, e.g HeLa, HaCaT, and NIH3T3 
cells, among others [215] could be improved by using sugars (e.g. glucose, trehalose, d-
allose). 
Trehalose as a complex sugar is a good candidate in cryopreservation since it provides 
protection to cell membranes and proteins [69], but efforts have been made to introduce 
trehalose inside cells [68, 70, 71] making the process time consuming and the results may 
vary within the experiments. As an alternative to trehalose, glucose is also used as 
cryoprotectant. Glucose is involved in various biological processes - e.g. glycolysis - which 
might cause undesired side-effects to the cryopreservation process, such as protein 
glycations.  
Dextran, like HES, is used in the clinical setting as a plasma expander and it is rapidly 
removed by the kidneys [89, 216]. As a cryoprotectant, dextran is a colloid that is well 
tolerated in the cryopreservation of organs [217, 218] without increasing the viscosity of the 
cryosolution [219] and in combination with low-potassium the solution can act as a free 





cryoprotective activity it is usually used in the freeze-drying of proteins [222], lipososomes 
[223] and chromatins [224] and in the vitrification of mammalian gametes [85]. It is unclear 
whether sorbitol is a non-penetrating or penetrating cryoprotectant. Two publications argue 
that sorbitol acts as an intracellular cryoprotectant since is able to penetrate the cell 
membrane [88] and cells have a sorbitol transport mechanism [225] while others consider 
sorbitol non-penetrating for most of the cells under normal conditions [87].  
Given this, we decided to use the sugars sorbitol and dextran in combination with HES for 
the cryopreservation of mesenchymal stem cells. Previously, we described the use of HES 
450 as cryoprotectant, but for the continuing experiments HES 200 was used. As we 
demonstrated previously HES molecular weight has no effect as cryoprotectant [226] and 
HES 200 is commonly used medically as a volume expander [227]. In the context of the 
study presented in this thesis sorbitol was selected to replace DMSO in the cryosolution. 
Therefore, a combination of sorbitol, dextran and HES were used as cryoprotectants 
replacing DMSO and serum from the cryosolution in the cryopreservation of MSCs. 
Stemness and viability were analyzed after cryopreservation. As basal media, ringer acetate 
or DMEM was used. Ringer acetate is an electrolyte solution, clinically acceptable, which is 
employed as a carrier solution or as volume replacement.  
Analysis of sorbitol, dextran and HES independently showed no efficient cryopreservation of 
MSC in a serum-free solution - DMEM. This can be explained by the lack of an intracellular 
cryoprotectant or serum leading to changes in osmosis, formation of ice and apoptosis. 
Addition of DMSO to any one of the independent solutions did not increase the 
cryopreservation efficiency which was not expected due to the effective cryoprotective role of 
DMSO. Others have been able to enhance cell recovery or reduce DMSO concentration 
when sorbitol, dextran or HES were used but in combinations with DMSO and/or serum [190, 
197, 228]. Serum is known to provide protection during the cryopreservation process but is 
still a xenogenous component that must be replaced for cell transplantation. 
The combination of sorbitol, dextran and HES in DMEM showed viability similar to DMSO in 
DMEM but still lower compared to instances where serum was used.  
Substitution of DMEM by ringer acetate clearly improves cell viability comparable to fresh 
control. Cryopreserved MSC in sorbitol, dextran and HES in ringer acetate were able to 
differentiate into osteogenic, adipogenic and chrondrogenic lineages showing that stemness 
was not affected by the cryopreservation process. The mechanism of action from these 
substances is not clearly understood. However, HES and dextran are able to reduce 
intracellular ice and both of them prevent hyperosmotic and hyposmotic damage into the 
cells [229].  
Furthermore, electrolyte solutions, e.g. ring acetate, can act as a substitute for cell culture 
media [230, 231]. DMEM as basal media for cryosolution contains several components such 
as amino acids, inorganic salts, vitamins and glucose which can be beneficial or detrimental 
for cryopreservation. Previous findings show that addition of amino acids to the 
cryoprotectant improved post-thaw motility and velocity of cryopreserved sperm [232-234] 
but at higher concentration increases the osmotic pressure [233]. DMEM uses have not been 
applied for therapeutic purposes and no study on human safety is available [235].  
To summarize these findings we demonstrated that DMSO, serum and DMEM can be 
successfully replaced by non-toxic and clinically approved solutions without interfering with 
the cellular functions and minimizing cell loss. A new cryosolution formulation based on 






5.2 The effect of cooling rates in the cryopreservation of cells 
During cryopreservation various factors are involved than can interfere with the proper 
cryopreservation of cells, one of them being the cooling rate of the sample. Various methods 
are available in the cryopreservation field where the temperature of cooling is defined to 
prevent and reduce intracellular ice formation such as controlled rate freezing, vitrification 
and the conventional method. The different methods must be optimized for the different cell 
types, tissues or organs to be cryopreserved since the same cooling rate cannot be applied 
for the different purposes. 
Controlled rate freezing allows us to manipulate and to control the temperature in which cells 
can be cryopreserved in a consistent way. It is known that slow freezing results in a higher 
cellular damage since an increase in electrolytes to a toxic level will be present as ice is 
formed extracellularly [236], and dehydration of the cells can also be observed [237]. Rapid 
freezing – vitrification - is suggested as a better choice for cryopreservation since intracellular 
water is retained preventing dehydration and freezing will occur intracellular and extracellular 
[2]. Additionally, the conventional method, known as Mr. Frosty Nalgene container, provides 
a constant freezing rate of 1°C/min.   
 
5.2.1 Cooling rate for Mesenchymal Stem Cells 
Mesenchymal stem cells were cryopreserved with 7 different freezing protocols: 6 
protocols from a controlled rate freezing machine and one protocol for “vitrification” 
which is directly placing cryovials into a vapour phase nitrogen tank. Comparison of 
the cooling effect between the different freezing protocols was performed by 
analysing cell viability after thawing and differentiation potential.  
Cell viability was analysed at day 0 and 3 after thawing. At day 0 cryopreserved MSC 
showed more than 80% cell recovery for all the protocols tested. Determination of 
cell viability at day 0 is very common in cryopreservation but it does not provide with 
the proper estimation of cell recovery for optimal cryopreservation efficiency as 
described in the previous section. Therefore, is crucial to analyse cell recovery over a 
period of time in culture.  
The cryopreserved MSC were allowed to recover for 3 days and cell viability was 
dependent of the cooling rate. The cell viability decreased compared to day 0 
indicating that during the recovery period of 3 days cell loss was evident. The 
decrease in cell number can be explained due to apoptosis or necrosis events which 
have been reported to occur after 6 hours of cells being thawed [139, 202, 238, 239]. 
A freezing protocol consisting of a constant cooling rate of 1°C/min until -30°C 
followed by 5°C/min until -80°C and protocols with a fast cooling rate (> 99°C/min) 
are the most suitable for the cryopreservation of MSC. Our results are consistent with 
findings by others in which cryopreservation of MSC were performed with slow 
cooling rates or directly into the liquid nitrogen tank [154, 157, 226] but full 
comparison between the different cryopreservation methods were not performed.   
A crucial range during cooling where nucleation and crystal ice growth exists is 
between 0°C to -40°C. Cooling of cells to -40°C without formation of intracellular ice 
can be accomplished only with cooling rates below 10°C/min [11]. To overcome this 





intracellular ice formation. However, a low cooling rate, which is found in most cases 
suggested for proper cryopreservation, allows for partial cell dehydration which can 
also prevent intracellular ice formation [240].  
In summary, cooling rate has an effect on cell recovery and differentiation of 
cryopreserved MSC. Ice nucleation and intracellular ice formation are both 
dependent on the cooling rate showing the importance of determining the proper 
freezing rate and release of heat from the cryosolution.  
In the studies presented here we concluded that slow (0.3°C - 1°C/min to -30°C) 
being below -30°C the critical point and rapid cooling (> 99°C/min) can be used to 
preserve viability and stemness of MSC.  
 
5.2.2 Cooling rates for fibroblasts and keratinocytes cryopreservation in suspension 
and adherent 
Reports available on the cryopreservation of fibroblasts and keratinocytes have not shown 
comparison between the freezing methods and cooling rates for the cryopreservation of 
these cells in suspension and as adherent cells. Therefore, fibroblasts and keratinocytes 
were cryopreserved in suspension and as adherents with 8 different freezing protocols: 6 of 
them controlled-rate freezing, directly into vapor phase of liquid nitrogen and by the 
conventional method.  
We found that viability at day 0 for the cryopreservation of human fibroblast cells and 
keratinocytes was dependent of the freezing protocol, slow cooling or placing them directly 
into the nitrogen tank being the most suitable. Given that viability at day 0 is not a reliable for 
determining proper cryopreservation, cell recovery was determined at day 3 after thawing. 
Keratinocytes showed higher cell viability with conventional method followed by controlled 
rate freezing. An enhancement in cell proliferation was observed for some freezing protocols. 
Increases in cell numbers have been reported for heart cells and chondrocytes after 
cryopreservation [241, 242]. During the stressful process of cryopreservation alteration within 
the cell might occur in which insusceptible populations of keratinocytes cells were selected 
during the cryopreservation process and cultivation period. Liu et al observed a temporary 
up-regulation of stress proteins, heat shock protein and growth factors after thawing thereby 
demonstrating the activation of stress response and inducers of proliferative capacity [120]. 
In our studies, keratinocytes cells were able to be cryopreserved in suspension with a cooling 
rate more than 100°C/min. Similar efforts were performed by others with no success of 
recovery [111, 149].  
Furthermore, keratinocytes cryopreserved as adherent cells showed higher cell viability at 
day 3 with slow cooling (1°C/min). The use of fast cooling (> 100°C/min) is possible but cell 
recovery is lower. Previous attempts to cryopreserve keratinocytes as adherent cells showed 
that viability is dependent on cooling rate: 3°C/min > 1°C/min > 10°C/min [150]. Ji 
demonstrated cryopreservation of adherent human embryonic stem cells [209], another cell 
type that resemble keratinocytes in cell size,  but not effort has been made to determine 
whether “vitrification” is possible for keratinocyte adherent cultures. 
The results clearly demonstrated differences in the cryopreservation of keratinocyte cells in 
suspension and as adherent cells which have never been clearly demonstrated before.  
In the studies presented here we compared cryopreservation of a fibroblast cell line versus 
primary fibroblasts culture. Viability determined at day 0 (directly after thawing) was protocol 





primary fibroblasts where slow and rapid cooling resulted in higher viability. Analysis of cell 
recover at day 3 showed that cooling rate of 0.5°C/min, conventional method and vitrification 
(straight freeze) for primary fibroblasts resulted in higher cell number compared to the 
fibroblast cell line. Cryopreservation of fibroblasts cells using slow cooling rates < 1°C/min 
have been accomplished by others but the use of vitrification showed no success [111, 138].  
The results obtained showed differences in cryopreservation of primary fibroblasts and 
fibroblasts cell line in suspension. A possible explanation for the differences is that a cell line 
is an immortalized cell that has an unlimited life span and growth capacity therefore they can 
behave distinctively than primary fibroblasts.  
Fibroblasts cryopreserved as adherent cells showed unexpected results. The proliferative 
capacity after thawing was greatly diminished for both primary fibroblasts and fibroblast cell 
lines. In some protocols cell detachment or deterioration was observed during the period of 3 
days in culture. Available data showed that cells preserved as adherent cells showed loss of 
metabolic activities and membrane integrity [243]. In addition, preservation of endothelial 
cells as adherent cells seems to be dependent on the cooling temperature in which at -196°C 
cell detachment and loss of membrane integrity was observed as compared to -80°C [244]. 
Cryopreservation of cells as adherent cells is still in development and more studies are 
necessary to determine the suitable cell culture plate and freezing protocols.  
In the freezing protocols used in this study, 2 protocols share a cooling rate of 1°C/min but 
the way in which this rate is accomplished differs. One protocol is based on the use of a 
controlled rate freezing machine while the other uses an isopropanol-based container named 
Mr Frosty. While we expected to obtain the same results for the cryopreservation of 
keratinocytes and fibroblasts differences were observed. Keratinocyte cells showed better 
cryopreservation with controlled rate freezing while fibroblasts preferred the use of the Mr. 
Frosty container demonstrating dissimilarity between the cell types. One can argue that the 
use of controlled rate freezing machine provides a more accurate and precise cooling than a 
freezing container which has as a constraint the “accuracy” temperature of a -80°C freezer. 
At the moment no one has reported whether variations within experiments are possible with 
controlled rate freezing machine since the cooling rate can be dependent on the sample or 
the machine. Researchers rely on records from the freezing programs always being available 
and that minimal variations can easily be noticed and interpreted.  
I suggest that fibroblast cells and keratinocytes can be cryopreserved using a slow freezing 
protocol for cryovials and that only keratinocytes be cryopreserved as adherent cells. Usage 
of slow freezing protocols have been shown to be beneficial for the storage of myoblasts 
[245], human embryonic stem cells [246], and cells derived from hematopoietic origins [247], 
among others. 
To summarize the findings the use of the Nalgene container Mr. Frosty and vitrification are 
the most convenient and cost-effective methods for the cryopreservation of fibroblasts and 
keratinocytes either in suspension or as adherent cells. Cryopreservation protocols cannot 
be applicable to all cell types as seen for primary fibroblasts and fibroblast cell lines, 
indicating that cooling rates are cell-dependent. In addition, we accomplished to 
cryopreserve fibroblasts and keratinocytes as adherent cells which can be further translated 










Fibroblasts, keratinocytes and mesenchymal stem cells are a useful tool in the field of 
regenerative medicine and tissue engineering due to their ability of being functional cell types 
of mesodermal lineage. Storing and banking of these cells can provide every potential patient 
with a source of allogeneic or autologous cells and tissues which are an important factor for 
cell replacement therapies and tissue production. 
The most effective way to preserve cells and tissues is by cryopreservation. It usually 
involves the use of compounds that can be cytotoxic (e.g. DMSO) or xenogeneous (e.g. 
serum). The perfect cryoprotectant agent is non-toxic, non-antigenic, chemically inert and 
provides a high viability rate. Given that, sugars and starches which are often used as natural 
cryoprotectors can be used as a cryoprotectant agent, thereby minimizing the adverse 
effects due to the presence of DMSO and/or serum in the cryosolution.  
Here I showed the development of a novel DMSO- and serum-free cryosolution for the 
cryopreservation of stem cells based on HES, sorbitol and dextran in Ringer Acetate. MSC 
differentiation potential and viability were not affected after cryopreservation demonstrating 
that these cells are still functional and that transplantation into the patient without negative 
effects and washing steps is hypothetically possible. 
Furthermore, several attempts in the cryopreservation field to find the perfect cooling rate 
and method are still in process. Full comparison of different freezing rates and methods were 
performed in this thesis for MSC, fibroblasts and keratinocyte cryopreservation. The three 
cell types can be cryopreserved with slow cooling and vitrification. The use of a controlled 
rate freezing machine which is expensive and time consuming is unnecessary. Cooling rate 
can affect cell viability and differentiation when cryo-injury is allowed to occur thereby 
affecting cell recovery after thawing. There is not one common freezing rate that can be 
applicable for the cryopreservation of MSC, fibroblasts and keratinocytes cells as observed in 
these studies.   
Furthermore, I clearly demonstrated that primary and cell line fibroblasts, being both the 
same cell type, differ in cryopreservation efficiency in suspension and as adherent cells, and 
being this thesis the first report to show that freezing protocols cannot be applicable for 









Fibroblasten, Keratinozyten und mesenchymale Stammzellen (MSC) sind Zellen 
mesenchymalen Ursprungs und stellen ein nützliches Werkzeug im Bereich der 
regenerativen Medizin und Tissue engineering (Gewebekonstruktion). Die Langerung dieser 
Zellen würde für potentielle Patienten eine Quelle für allogene oder autologe Zellen und 
Gewebe darstellen, dies wäre ein wichtiger Faktor für Zelltherapien und die Herstellung von 





Kryokonservierung. Ein  großer Nachteil ist, dass die verwendeten Komponenten zur 
Kryokonservierung, zytotoxisch (z.B. DMSO) oder xenogen (z.B. Serum) sind.  
Die perfekten Kryoportektaten darstellen, zur Kryokonservierung genutzt werden und 
dadurch den schädlichen Effekt durch die Verwendung von DMSO und/or Serum in der 
Kryolösung verringern. 
MSC sind  empfindlicher gegenüber der Kryolösung als vergleichsweise Fibroblasten und 
Keratinozyten; eine Beeinträchtigung der Stammzelleingenschaften der MSC führt zu einer 
Verringerung des Differenzierungspotentials der MSC und der Expression der Marker. Aus 
diesem Grund wird in der vorliegenden Arbeit die Entwicklung einer neuen, DMSO- und 
Serumfreien Kryolösung auf der Basis von HES, Sorbitol und Dextran in der Ringer-Lösung 
die Kryokonservierung von MSC beschrieben. Das  Differenzierungspotential und die Vitalität 
von MSC wurden nicht beeinflusst durch die Kryokonservierung. Dies zeigt, dass diesen 
Zellen immer noch funktionell sind und eine Transplantation in den Patienten wäre ohne 
negative Effekte und Waschschritte möglich. 
Darüber hinaus werden derzeit in der Kryokonservierung verschiedene Ansätze erforscht, 
um die perfekte Kühlrate und Methoden zu etablieren. Es wurden in dieser Arbeit 
verschiedene Kühlraten und Methoden für die Kryokonservierung von MSC, Fibroblasten 
und Keratinozyten miteinander verglichen. Diese Zelltypen können mit langsamer Kühlrate 
(1°C/min) und Vitrifikation (>100°C/min) kryokonserviert werden. Die Verwendung von 
Maschine mit kontrollierter Einfrierrate, die teuer und aufwendig sind, erwies sich als unnötig. 
Die Einfrierrate wirkt sich auf die Erholung von MSC, Fibroblasten und Keratinozyten über 
einen längeren Kultivierungszeitraum aus. Zusätzlich wurde eine Verbesserung der 
Proliferationskapazität von Keratinozyten beobachtet. Das Differenzierungspotential von 
MSC war abhängig von der Einfrierrate. Diese Studien zeigen, dass es keine allgemein 
anwendbare Einfrierrate    für MSC, Fibroblasten und Keratinozyten gibt. 
Zusätlich konnte ich zeigen, dass sich die Effizienz bei der Kryokonservierung von primäre 
und sekundäre (Zelllinie) Fibroblasten in Suspension und als anhaftenden unterscheidet, 
obgleich beide den gleichen Zelltyp darstellen. In dieser Arbeit wurde damit zum ersten Mal 
gezeigt, dass die Protokolle zur Kryokonservierung für primäre Zellen und sekundäre Zellen 
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